🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire Dijon
NCT06600308 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Facioscapulohumeral muscular dystrophy (FSH) is one of the most common genetic myopathies in adults. It is characterised by progressive asymmetric muscular atrophy affecting the skeletal muscles of the face, upper limbs and then lower limbs, causing problems with walking, which is one of the most frequent complaints of these patients. In fact, 20% of people with FSH require a wheelchair from the age of 60. To date, scientific research into FSH has focused mainly on the molecular level, enabling potential therapeutic targets to be identified. Trials of gene therapies and other drug therapies are gradually emerging, with the aim of having a positive impact on these people\'s functional abilities, particularly walking difficulties. However, few studies have looked at the functional impact of FSH on these people, and in particular at the specific analysis of their walking ability In Fran

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Patient : * Adult ; * Having given written consent; * With an established molecular genetic diagnosis of FSH; * Able to understand the instructions for carrying out the various tests; * Able to walk for at least 6 minutes, even intermittently; Exclusion Criteria: Patient : * Not affiliated to or not benefiting from a social security scheme; * With one or more cardiorespiratory contraindications to a 6-minute test; * With another neuro-orthopaedic history (other than FSH) that could significantly compromise walking ability; * With cognitive problems preventing them from performing standardised tasks; * Under legal protection (curatorship, guardianship). * Who are subject to a legal protection measure; * Pregnant, parturient or breast-feeding woman; * Unable to benefit from longitudinal follow-up (D15 and M6).
💊

What it tests

  • Walk tests
  • ecological (real-life) assessment of walking ability
📍

Where

1 site
Chu Dijon Bourgogne
Dijon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy